Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2021 17:07 ET | Source: Vaccitech Limited

Vaccitech Announces Closing of $110.5 Million Initial Public Offering

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
April 29, 2021 18:49 ET | Source: Vaccitech Limited

Vaccitech Announces Pricing of Initial Public Offering

OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
March 22, 2021 04:00 ET | Source: Vaccitech Limited

Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors

OXFORD, United Kingdom, March 22, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
March 18, 2021 03:00 ET | Source: Vaccitech Limited

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

OXFORD, United Kingdom, March 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...
March 17, 2021 03:00 ET | Source: Vaccitech Limited

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
March 02, 2021 03:00 ET | Source: Vaccitech Limited

Vaccitech Appoints Two Independent Board Directors

OXFORD, United Kingdom, March 02, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...
February 01, 2021 03:00 ET | Source: Vaccitech Limited

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...
November 23, 2020 03:23 ET | Source: Vaccitech Limited

Oxford University breakthrough on global COVID-19 vaccine

OXFORD, United Kingdom, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Vaccitech’s scientific founders at University of Oxford announce positive high-level results from an interim analysis of clinical trials of...

keyboard_arrow_left Previous Page